HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Approved Indications for Biosimilar Inflectra

In this slideshow, we summarize the approved indications for the rheumatology biosimilar Inflectra (infliximab-dyyb), the boxed warnings and possible side effects.

The U.S. Food and Drug Administration approved Inflectra (infliximab-dyyb) on April 5, 2016 for six indications. Prescribing information from the FDA: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125544s000lbl.pdf